Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cipralisant is a selective histamine H3 receptor antagonist in vivo, and an agonist in vitro (pKi: 9.9 for histamine H3 receptor; Ki: 0.47 nM for rat histamine H3 receptor). It has the potential for the treatment of attention-deficit hyperactivity disorder.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 13,900 | 8-10周 | ||
50 mg | ¥ 18,300 | 8-10周 | ||
100 mg | ¥ 23,500 | 8-10周 |
产品描述 | Cipralisant is a selective histamine H3 receptor antagonist in vivo, and an agonist in vitro (pKi: 9.9 for histamine H3 receptor; Ki: 0.47 nM for rat histamine H3 receptor). It has the potential for the treatment of attention-deficit hyperactivity disorder. |
靶点活性 | H3 receptor (rat):(ki)0.47 nM, H3 receptor:(pki)9.9 |
体外活性 | Cipralisant acts as a full agonist at the recombinant rat histamine H3 receptor in vitro and potently inhibits forskolin-induced cAMP accumulation (EC50: 0.23 nM). Cipralisant increases the basal [35S]GTPγS binding activities in membranes from HEK cells expressing the rat histamine H3 receptor (EC50: 5.6 nM) [2]. |
体内活性 | Cipralisant (10 mg/kg, p.o.) blocks R-α-methylhistamine (a histamine H3 receptor agonist)-induced water intake in rats [2]. |
别名 | GT-2331 |
分子量 | 216.32 |
分子式 | C14H20N2 |
CAS No. | 213027-19-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cipralisant 213027-19-1 Others GT2331 GT-2331 GT 2331 Inhibitor inhibitor inhibit